A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia by Shorr, Andrew F et al.




A risk score for identifying methicillin-resistant












See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Shorr, Andrew F.; Myers, Daniela E.; Huang, David B.; Nathanson, Brian H.; Emons, Matthew F.; and Kollef, Marin H., ,"A risk score




Andrew F. Shorr, Daniela E. Myers, David B. Huang, Brian H. Nathanson, Matthew F. Emons, and Marin H.
Kollef
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/1515
RESEARCH ARTICLE Open Access
A risk score for identifying methicillin-resistant
Staphylococcus aureus in patients presenting to
the hospital with pneumonia
Andrew F Shorr1*, Daniela E Myers2, David B Huang3, Brian H Nathanson4, Matthew F Emons5 and Marin H Kollef6
Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) represents an important pathogen in healthcare-
associated pneumonia (HCAP). The concept of HCAP, though, may not perform well as a screening test for MRSA
and can lead to overuse of antibiotics. We developed a risk score to identify patients presenting to the hospital
with pneumonia unlikely to have MRSA.
Methods: We identified patients admitted with pneumonia (Apr 2005 – Mar 2009) at 62 hospitals in the US. We
only included patients with lab evidence of bacterial infection (e.g., positive respiratory secretions, blood, or pleural
cultures or urinary antigen testing). We determined variables independently associated with the presence of MRSA
based on logistic regression (two-thirds of cohort) and developed a risk prediction model based on these factors.
We validated the model in the remaining population.
Results: The cohort included 5975 patients and MRSA was identified in 14%. The final risk score consisted of eight
variables and a potential total score of 10. Points were assigned as follows: two for recent hospitalization or ICU
admission; one each for age < 30 or > 79 years, prior IV antibiotic exposure, dementia, cerebrovascular disease,
female with diabetes, or recent exposure to a nursing home/long term acute care facility/skilled nursing facility. This
study shows how the prevalence of MRSA rose with increasing score after stratifying the scores into Low (0 to 1
points), Medium (2 to 5 points) and High (6 or more points) risk. When the score was 0 or 1, the prevalence of
MRSA was < 10% while the prevalence of MRSA climbed to > 30% when the score was 6 or greater.
Conclusions: MRSA represents a cause of pneumonia presenting to the hospital. This simple risk score identifies
patients at low risk for MRSA and in whom anti-MRSA therapy might be withheld.
Background
Methicillin-resistant Staphylococcus aureus (MRSA) is
an important pathogen in a number of conditions ran-
ging from pneumonia to bacteraemia [1]. In critically ill
patients, MRSA accounts for more than 70% of the S.
aureus isolated [1,2]. Because of the multitude of infec-
tions associated with MRSA along with its potential
severity, this pathogen results in substantial morbidity
and mortality [1].
MRSA has often been implicated as a cause of either
hospital-acquired or ventilator-associated pneumonia
(HAP or VAP) [3]. In contrast, Streptococcus pneumoniae,
Haemophilus influenzae, and Legionella spp. historically
represent themost commonbacterial causes of community-
acquired pneumonia (CAP) [4]. However, a number of
bacteria historically thought confined to nosocomial pro-
cesses are increasingly isolated in community-onset infec-
tions. This trend fostered the creation of the concept of
healthcare-associated pneumonia (HCAP) [3]. Although
both patients with HCAP and CAP suffer the onset of
their infections outside the hospital, those with HCAP
are distinct because of their ongoing exposure to the
healthcare system.
Unfortunately, reliance on the notion of HCAP to guide
the use of broader spectrum antibiotics may result in
overutilization of such agents. Moreover, HCAP as cur-
rently defined, appears to lack specificity as a screening
test for resistant pathogens [5-7]. Prior studies evaluating
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risk factors for resistant pathogens in pneumonia present-
ing to the hospital suggest that grouping Gram-negative
organisms such as Pseudomonas aeruginosa together with
MRSA may be inappropriate [5-7]. These distinct patho-
gens possess different risk factors, or select risk factors for
resistance may carry differential significance for the vary-
ing organisms. For example, theoretically, nursing home
residence may be associated more with MRSA than P.
aeruginosa [8]. Additionally, clinicians are able to either
add or withhold anti-MRSA therapy without compromis-
ing the extent of the Gram-negative coverage. The deci-
sion to prescribe an anti-MRSA agent can be decoupled
from the option of Gram-negative treatment. Several
agents exist which possess only Gram-positive activity and
are essentially employed only for their anti-MRSA proper-
ties. Thus, it seems prudent to better recognize the spe-
cific variables that are associated with an increased risk for
MRSA. Understanding these patient characteristics would
more precisely allow clinicians to segregate persons at risk
for MRSA from those unlikely to be infected with MRSA.
Furthermore, identifying those at low risk for MRSA
would facilitate antibiotic stewardship by rationally limit-
ing unnecessary anti-MRSA therapy which would help
contain costs and reduce future antibiotic resistance [9].
Therefore, we conducted a retrospective analysis in order
to develop a score to stratify patients presenting to the
hospital with pneumonia by their risk for MRSA infection.
Methods
Study overview and patients
We conducted a multi-centre, retrospective analysis of pa-
tients admitted to the hospital with pneumonia between
April 2005 and March 2009. The data are from 62 hospi-
tals in the United States (US) via the Cerner Health Facts
database (see Additional file 1). We included adults
with a primary discharge diagnosis of pneumonia or a
primary diagnosis of sepsis with a secondary diagnosis
of pneumonia and no other source of infection by
International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes (see Additional
file 2). The codes were selected based on existing pub-
lished studies [10-12] in combination with clinical judg-
ment. We excluded those younger than 18 years of age
and individuals with only nosocomial pneumonia (e.g.,
HAP, VAP). Nosocomial pneumonia was defined as occur-
ring within 48 hours of hospitalization in accordance with
the ATS/IDSA definitions [3]. We only included persons
with pneumonia and laboratory confirmation of a bacterial
aetiology. Presence of a bacterial aetiology was determined
based on a review of electronic health records for culture
results (blood, respiratory secretions, pleural fluid) and
urinary antigens for either S. pneumoniae or Legionella
spp. We only reviewed cultures obtained within 48 hours
of admission. The database contains only de-identified
data and is HIPAA compliant. Because of this and the
nature of the present analysis (review of existing records),
this study was classified as exempt from Institutional
Review Board (IRB) review.
Endpoints and covariates
The isolation of MRSA served as our primary endpoint.
We compared those with MRSA to those infected with
other bacterial organisms. Patients with MRSA isolated
along with another pathogen were counted as MRSA for
the purposes of this study. Polymicrobial status (more than
one isolate) was captured as a separate variable in the
study. The determination of methicillin-resistance was
made at each individual site in accordance with local la-
boratory practices. We collected information regarding pa-
tient demographics, co morbidities (based on ICD-9-CM
codes), severity of illness, and source of admission. Need
for intensive care unit (ICU) admission represented our
primary measure of disease severity. We identified patients
(based on ICD-9-CM codes) with coronary artery disease
(CAD), congestive heart failure (CHF), diabetes mellitus
(DM), chronic obstructive pulmonary disease (COPD),
stroke, dementia, or chronic kidney disease necessitating
haemodialysis (HD). We calculated Charlson Co morbidity
scores to determine the extent of co morbidities [13]. We
additionally categorized patients as to whether they met
criteria for HCAP [3]. We defined HCAP as present if any
one of the following criteria were met: nursing home,
long term acute care facility, or skilled nursing facility
(NH/LTC/SNF) exposure within the last 90 days, recent
hospitalization in the last 90 days with length of stay ≥
2 days, prior intravenous antibiotic therapy or wound
care in the last 30 days prior to admission, chronic HD,
or a history of immunosuppression. Chronic HD per-
sons were identified as those who have undergone
dialysis at any setting plus a diagnosis of chronic kidney
disease (based on ICD-9-CM codes) within 30 days
prior to the index admission or during index admission.
Based on clinical expertise, we classified immunosup-
pressed persons as those who had: 1) recent or current
treatment with systemic corticosteroids or other im-
munosuppressive/chemotherapy agents; 2) a diagnosis
of human immunodeficiency disease (HIV), leukaemia/
lymphoma, or metastatic cancer, or 3) had undergone a
solid/liquid organ transplant. All patients not fulfilling
the HCAP definition were categorized as CAP.
Statistics and risk score development
For continuous variables, MRSA and non-MRSA patients
were compared with either the Student’s t-test or
Wilcoxon 2-sample test, as appropriate. Categorical data
were analyzed with either the chi-square test or the
Fisher’s exact test. We defined a p-value of <0.05 to repre-
sent statistical significance.
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For risk score development and validation, we employed
a split sample approach. The entire population was
randomly split into a development cohort (two-thirds of
patients) and a validation cohort (remaining one-third of
patients). We then utilized a bootstrapping based, stepwise
logistic regression procedure on the development cohort
to determine variables most strongly associated with
MRSA [14]. We also assessed plausible interaction terms
between various co morbidities as well as co morbidities
and gender in a series of models. In each stepwise regres-
sion model, a p-value of 0.05 was required for entry into
the model and a p-value of 0.1 to remain in the model.
The stepwise algorithm was applied to 100 bootstrapped
samples in the development set and each time the variable
entered the model, this was recorded. Variables that con-
sistently entered the model were kept for further analysis.
The final 8 variables that comprised the risk score were
those that entered the samples most often and had face
validity for clinical relevance.
In the final risk score the standardized coefficients
from the logistic regression represented the weight
assigned to each predictor variable. Specifically, we fully
standardized the coefficients of each variable in the final
logistic regression model (i.e., they were standardized on
the X and Y variables). Based on the standardized coeffi-
cients, we rounded up to get integer “point values” for
the score with the smallest standardized coefficients get-
ting a point value of 1 for ease of computation at the
bedside. We then validated the risk score in the valid-
ation cohort, determining the prevalence of MRSA as a
function of the score. We also examined traditional
model performance characteristics (e.g., the area under
the receiver operating characteristic curve [AUROC]).
Results
The final study population (both development and valid-
ation cohorts) included 5975 patients. MRSA occurred in
14.0% (n = 837) of patients. Other commonly recovered
Table 1 Patient characteristics
MRSA No MRSA p
(n = 837) (n = 5138)
Demographics
Age, mean ± SD, years 69.4 ± 17.1 67.1 ± 17.0 <0.001
Male, % 53.4% 55.7% 0.435
Race 0.606
Caucasian, % 80.6% 82.1%
African-American, % 14.6% 13.4%
Other/Unknown, % 4.8% 4.5%
Co morbid illnesses (current or prior to index admission unless noted)
Hypertension, % 56.2% 52.8% 0.075
Diabetes mellitus, % 28.0% 25.4% 0.117
Coronary artery disease, % 29.2% 27.6% 0.358
Congestive heart failure, % 35.0% 26.8% <0.001
Chronic obstructive pulmonary disease, % 50.1% 44.7% 0.004
Malignancy (includes lymphoma, myeloma, secondary neoplasm), % 13.7% 14.% 0.433
Cerebrovascular disease (any) prior to index admission, % 10.6% 5.0% <0.001
Ischemic stroke prior to index admission, % 5.0% 3.2% 0.007
Dementia, % 9.3% 4.6% <0.001
Chronic haemodialysis, % 21.1% 15.6% <0.001
Healthcare-associated risk factors
Nursing home/skilled nursing facility/long term acute care exposure within last 90 days, % 25.9% 11.4% <0.001
Hospital-based wound care within 30 days prior to index admission, % 5.38% 1.32% <0.001
Recent hospitalization (for ≥ 2 days and within the last 90 days), % 38.7% 21.7% <0.001
Prior intravenous antibiotic therapy within the last 30 days, % 5.4% 1.3% <0.001
Immunosuppression, % 23.4% 16.2% <0.001
Severity of illness
Intensive care unit admission (on or before index culture), % 22.9% 14.9% <0.001
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pathogens included: S. pneumoniae (17.5%), P. aeruginosa
(13.8%), methicillin-sensitive S. aureus (13.7%), Escherichia
coli (6.0%), and H. influenzae (5.6%). As Table 1 demon-
strates, in the overall sample patients with MRSA were
older and suffered from more co morbidities. Every
chronic condition of interest, other than malignancy,
occurred more often in patients with MRSA compared
to those patients without MRSA. Reflecting this, the
Charlson Co morbidity score [mean, standard deviation
(SD)] was higher among patients with MRSA compared to
no MRSA [(2.6, 2.2) versus (2.2, 2.1), p < 0.001]. A signifi-
cant portion of MRSA versus no MRSA patients had an
ICU admission on or before their index culture (22.9 ver-
sus 14.9%, p < 0.001).
Nearly 40% of those presenting to the hospital with
pneumonia met criteria for HCAP, and the prevalence of
MRSA was substantially higher in HCAP. Those with
HCAP were 1.7 times (95% Confidence Interval (CI): 1.5-
2.0) more likely to be infected with MRSA than persons
classified as CAP (Figure 1).
The final logistic regression model consisted of eight
variables and included demographics, prior healthcare
exposure, disease acuity, and select co morbid condi-
tions. Table 2 summarizes the risk score for MRSA
pneumonia and the designation of points. Variables
more strongly linked with MRSA (based on relative
risks) included a recent inpatient hospitalization for ≥
2 days within the last 90 days and need for ICU admis-
sion (see Additional file 3). The HCAP variable was an
independent predictor of MRSA but not as strong a pre-
dictor as some of its components; therefore, it ultim-
ately was not included in the final model. The total
possible score ranged from 0 to 10. Figure 2 shows how
the prevalence of MRSA rose with increasing score in
both the development and validation cohorts after
stratifying the scores into Low (0 to 1), Medium (2 to 5)
and High (≥ 6) risk. When the score was ≤1, the preva-
lence of MRSA was < 10% while the prevalence of
MRSA climbed to > 30% when the score was ≥ 6. Of
note, the Low Risk subgroup (score of ≤1) represents
57.7% of the overall sample (e.g. both development and
validation cohorts). In addition, in the overall sample,
100% of the patients in the High risk group have HCAP
versus 18.17% in the Low risk group, p < 0.001.
As a screening test, a score of ≤1 versus greater than 1
had a sensitivity and specificity of 59.1% and 60.0%
respectively. The positive predictive value was low at
19.2% but the negative predictive value equalled 90.1%.
The pre-test probability for MRSA was approximately
14% (e.g., the prevalence of MRSA in the overall cohort).
With a ≤1 classification threshold, patients with a score ≤1
would have a post-test (posterior) probability of MRSA of
10% (a reduction in risk of approximately one-third) and
the post-test probability of MRSA would be 19.4% for
those with scores >1. The AUROCs of this model in the
development and validation cohorts were 0.66 (95% CI:
0.63, 0.68) and 0.64 (95% CI: 0.60, 0.67), respectively.
Discussion
This large retrospective analysis of microbiologically-
confirmed culture positive pneumonia patients presenting
to the hospital reveals that MRSA constitutes an impor-
tant pathogen in this setting. Similarly, HCAP accounts
for a large proportion of all pneumonia patients admitted
to the hospital and is nearly as common as CAP. Even
though patients with HCAP face an increased risk for
MRSA, the prevalence of MRSA in HCAP was less than
20%. A risk scoring tool based on factors independently
associated with the recovery of MRSA segregates patients
with moderate accuracy. A low total score describes a co-
hort of individuals unlikely to have MRSA and in whom
anti-MRSA therapy can likely be withheld.
Our data add to the growing evidence elucidating the
frequency of HCAP relative to CAP. In the initial study
examining the epidemiology of HCAP, HCAP accounted
for approximately one-third of all pneumonias presenting
to the emergency department (ED) [15]. Other reports
have documented that HCAP represents between 30%
and 60% of pneumonias initially evaluated in the ED [5-7],
and this trend is also observed in Asia and Europe [9,16].
Our study confirms that MRSA is a common pathogen in
patients presenting to the hospital with their pulmonary
infections. Classically thought only to be significant in
nosocomial infections, it is now evident that physicians
treating those who come to the hospital with pneumonia
must consider MRSA when selecting antibiotic regimens.
Originally, the notion of HCAP was developed to help
with this decision making process [3]. The specific com-
ponents of the HCAP definition were derived from ex-
pert opinion and were initially adopted from a single
centre study in bacteraemia [3,17]. HCAP was meant to
serve as a tool to help clinicians stratify individuals as to
the chance that a resistant pathogen, like MRSA, was a
practical issue. Our finding that there are many patients
Figure 1 Prevalence of methicillin-resistant Staphylococcus
aureus in community-acquired and healthcare-associated
pneumonia.
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with HCAP who are not infected with MRSA suggests
that HCAP alone cannot serve as a precise tool for risk
stratification. Our findings further confirm the observa-
tions of earlier researchers. For example, Schrieber and
colleagues found that HCAP performed poorly as a
screening test for MRSA in persons presenting to the
hospital with severe pneumonia necessitating mechan-
ical ventilation [6]. Shorr et al. similarly found that
HCAP misclassified many patients both as to their risk
for resistant pathogens in general, and for MRSA, specif-
ically [5]. Thus, it appears that broad use of the HCAP
criteria for classification can lead to overuse of broad
spectrum antibiotics which can result in unnecessary
cost and antimicrobial resistance.
The proposed risk score is novel and improves on the
status quo, as it provides a means for reliably classifying
quickly and easily a large cohort of patients at low risk
for MRSA. Since anti-MRSA therapies can often be added
or withheld without necessarily adjusting the selected
Gram-negative coverage, having an effective way to limit
the prescription of anti-MRSA treatments becomes cru-
cial. The situation with respect to anti-MRSA treatment
options is even more acute given their costs and potential
side effects.
Prior reports have proposed alternate risk scoring
schemes for determining the probability of resistant or-
ganisms in those coming to the hospital with pneumonia
[5-7]. However, most of these studies have pooled resistant
Gram negative organisms (e.g., P. aeruginosa) with MRSA
[5-7]. Our effort is therefore unique in that we have exam-
ined MRSA specifically. Our results are also novel in that
we identify several factors associated with MRSA that have
not previously been linked to pneumonia with this pa-
thogen. For example, extremes of age have not been previ-
ously described as related to MRSA in pneumonia.
Likewise the description of a nexus between certain co
morbid diseases, such as cerebrovascular disease (CVD)
and dementia, with MRSA has not been noted before in
evaluations of pneumonia in the ED. The mechanism of
these associations with MRSA is unclear. These specific
factors might actually represent surrogates for other
factors that we could neither address nor measure in
the dataset. Additionally, it appears that not all factors
contribute equally to the risk for MRSA as a cause of
pneumonia on hospital presentation. Intense exposure
to the healthcare system (e.g., recent inpatient stay)
seems disproportionately important as does severity of
illness. Moreover, different risk scores utilized thus far
in pneumonia (e.g., CURB-65) focus solely on severity
of illness while our risk score specifically deals with is-
sues of aetiology.
Our study has several strengths. It is based on a large
sample from multiple hospitals across the US. This provides
Table 2 MRSA risk score for methicillin-resistant Staphylococcus aureus in pneumonia
Variable Points
Age
Age < 30 years or > 79 years 1
Prior healthcare exposure
Recent hospitalization (for ≥ 2 days and within the last 90 days) 2
Nursing home/skilled nursing facility/long term acute care exposure within last 90 days 1
Prior IV antibiotic therapy within the last 30 days 1
Severity of illness
Intensive care unit admission (on or before index culture) 2
Co morbid illness
Cerebrovascular disease (any), prior to admission 1
Dementia 1
Female with diabetes mellitus 1


















Development Set; N = 3,993 Validation Set; N = 1,982
Figure 2 Prevalence of methicillin-resistant Staphylococcus
aureus among patients presenting with pneumonia to the
hospital as a function of the total risk score.
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us the power to examine select conditions that other ana-
lyses could not evaluate because of their smaller size. It
also suggests the generalizability of our findings. We have
also internally validated the proposed risk score. No other
effort has applied such a split sample approach in pneu-
monia presenting to the hospital. In fact, many risk strati-
fication schemes for other disease states never undergo
any effort at either internal or external validation.
Conversely, the present investigation has a number of sig-
nificant limitations. First, its retrospective nature exposes it
to several forms of bias. This is particularly concerning since
we relied on ICD-9-CM coding to identify patients with
pneumonia or a primary diagnosis of sepsis with a second-
ary diagnosis of pneumonia. There certainly are patients we
included who likely had some alternate diagnosis. Second,
culture data are not always obtained in every case of
suspected pneumonia which introduces a selection bias. A
priori, physicians may have preferentially opted to obtain
cultures in patients when they were already concerned about
resistant pathogens. Moreover, cultures can be negative
even in the presence of active bacterial infection and
positive cultures of the respiratory tract can represent
colonization and not true infection. Again, this raises the
concern that we could have misclassified patients. On the
other hand, since we only studied culture positive patients,
our findings likely underestimate the potential for anti-
biotic overuse and abuse. Third, we did not evaluate pa-
tients for co-infection with viral pathogens which could
have influenced our findings, especially as a risk factor for
MRSA infection. Fourth, despite our attempt to evaluate
all components of the HCAP definition, we likely
miscategorised some patients because of inadequate infor-
mation regarding recent IV antibiotic exposure since ad-
ministrative datasets may not consistently capture this.
Some of the factors identified, such as dementia, could
represent surrogates for other characteristics about which
we lacked data. Finally, our score had only moderate dis-
criminatory power and requires external validation. Al-
though it identified a group of persons as low risk for
MRSA, our data illustrate that there is a clear need for
better tools for this purpose and that we urgently require
rapid diagnostic tests for organism identification.
Conclusions
MRSA represents a cause of pneumonia presenting to the
hospital. A simple risk score for identifying MRSA in pa-
tients presenting to the hospital with pneumonia identifies
those at low risk for MRSA and may facilitate efforts to
better direct antibiotic prescribing.
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